Clinical Trial

A Clinical Study to Evaluate the Efficacy and Safety of Frevecitinib (KN-002) in Patients With Severe Asthma

Name: A Clinical Study to Evaluate the Efficacy and Safety of Frevecitinib (KN-002) in Patients With Severe Asthma — clinical trial record (NCT07532265)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: PANAIRAMA

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

A Phase 2 Dose Ranging Study to Evaluate the Efficacy and Safety of Frevecitinib (KN-002) Over a 12-Week Treatment Period in Patients With Severe Asthma Not Controlled With Medium to High Dose ICS/LABA

Protocol Amendment History 1 change

critical Recruitment opened 2026-07-25

Trial Details

NCT Number	NCT07532265
Lead Sponsor	Kinaset Therapeutics Inc
Conditions	Severe Asthma
Enrollment	512 participants
Start Date	2026-07-16
Primary Completion	2027-11-30 (estimated)
Study Completion	2027-11-30 (estimated)
Updated on ClinicalTrials.gov	2026-07-28